COLUMVI Market Summary

Key Factors Driving COLUMVI Growth

1. Rapid uptake in relapsed/refractory DLBCL is establishing a strong commercial base:

COLUMVI is a CD20xCD3 T-cell-engaging bispecific antibody approved for adults with relapsed/refractory DLBCL after ≥2 prior systemic therapies. The initial FDA accelerated approval was supported by a 56% objective response rate (ORR), including a 43% complete response (CR) rate), with a median duration of response of 18.4 months. Roche reported COLUMVI sales of CHF 196 million in H1 2026, up 70% at constant exchange rates, demonstrating rapid commercial uptake.

2. The fixed-duration, off-the-shelf treatment model provides differentiation from CAR-T therapy:

COLUMVI is administered as a limited-duration therapy, rather than requiring individualized cell collection and manufacturing. This can be particularly relevant for patients who need readily available treatment or are not candidates for transplantation/CAR-T. Roche specifically describes the GemOx regimen as an off-the-shelf and fixed-duration option for transplant-ineligible patients. The treatment therefore addresses a population where logistical limitations of cellular therapies can be important.

3. Strong clinical efficacy in heavily pretreated patients supports continued use in later-line disease:

The pivotal NP30179 study enrolled patients who had received a median of three previous lines of therapy. COLUMVI produced a 56% ORR and 43% CR rate, while responses were durable, with a median DOR of 18.4 months. This is particularly relevant because heavily pretreated DLBCL patients have limited therapeutic options. The FDA also identified cytokine release syndrome (CRS) and neurologic toxicity as important safety considerations, meaning appropriate step-up dosing and monitoring remain integral to treatment.

4. Geographic expansion is accelerating revenue growth:

COLUMVI + GemOx has been approved in 49 countries, including the EU, UK, Australia and Canada, according to Roche. This substantially expands the commercial footprint beyond the original later-line indication. Roche's H1 2026 results show COLUMVI sales of CHF 196 million, with CHF 91 million in the US (+28%) and CHF 105 million internationally, where growth was particularly strong.

COLUMVI Recent Developments

In April 2025, the European Commission approved COLUMVI + gemcitabine/oxaliplatin (GemOx) for adults with R/R DLBCL who are ineligible for autologous stem-cell transplantation. This moved COLUMVI into an earlier treatment setting. In the Phase III STARGLO study, COLUMVI + GemOx reduced the risk of death by 41% (HR 0.59) versus rituximab + GemOx and reduced the risk of progression or death by 63% (HR 0.37). At 20.7 months' follow-up, median overall survival was 25.5 vs 12.9 months, supporting broader adoption of the regimen.

“COLUMVI Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of COLUMVI for approved indication like Diffuse large B cell lymphoma; as well as potential indication like Mantle-cell lymphoma, B-cell lymphoma, Chronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin’s lymphoma, Richter’s syndrome, and Haematological malignancies in the 7MM. A detailed picture of COLUMVI’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the COLUMVI for approved and potential indications. The COLUMVI market report provides insights about COLUMVI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current COLUMVI performance, future market assessments inclusive of the COLUMVI market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of COLUMVI sales forecasts, along with factors driving its market.

COLUMVI Drug Summary

COLUMVI is a CD20xCD3 bispecific T-cell engager antibody developed by Genentech, a member of the Roche Group, for the treatment of certain patients with relapsed or refractory B-cell lymphomas. It is designed to simultaneously bind CD20 on malignant B cells and CD3 on T cells, bringing T cells into close proximity with tumor cells and activating the immune system to induce T-cell-mediated killing of CD20-positive B cells. COLUMVI is administered by intravenous infusion using a step-up dosing regimen, which is intended to reduce the risk and severity of cytokine release syndrome (CRS). In the United States, COLUMVI is approved for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy; it received accelerated approval based on response rates and durability of response. Treatment is associated with potentially serious adverse events, particularly CRS and immune effector cell-associated neurotoxicity syndrome (ICANS), as well as serious infections, tumor lysis syndrome, and prolonged cytopenias, necessitating appropriate monitoring and supportive care. The report provides COLUMVI’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the COLUMVI Market Report

The report provides insights into:

• A comprehensive product overview including the COLUMVI MoA, description, dosage and administration, research and development activities in approved indications like Diffuse large B cell lymphoma; as well as potential indication like Mantle-cell lymphoma, B-cell lymphoma, Chronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin’s lymphoma, Richter’s syndrome, and Haematological malignancies.
• Elaborated details on COLUMVI regulatory milestones and other development activities have been provided in COLUMVI market report.
• The report also highlights COLUMVI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The COLUMVI market report also covers the patents information, generic entry and impact on cost cut.
• The COLUMVI market report contains current and forecasted COLUMVI sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The COLUMVI market report also features the SWOT analysis with analyst views for COLUMVI in approved and potential indications.

Methodology

The COLUMVI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

COLUMVI Analytical Perspective by DelveInsight

• In-depth COLUMVI Market Assessment

This COLUMVI sales market forecast report provides a detailed market assessment of COLUMVI for approved indication like Diffuse large B cell lymphoma; as well as potential indication like Mantle-cell lymphoma, B-cell lymphoma, Chronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin’s lymphoma, Richter’s syndrome, and Haematological malignancies in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted COLUMVI sales data uptil 2034.

• COLUMVI Clinical Assessment

The COLUMVI market report provides the clinical trials information of COLUMVI for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

COLUMVI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

COLUMVI Market Potential & Revenue Forecast

• Projected market size for the COLUMVI and its key indications
• Estimated COLUMVI sales potential (COLUMVI peak sales forecasts)
• COLUMVI Pricing strategies and reimbursement landscape

COLUMVI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• COLUMVI Market positioning compared to existing treatments
• COLUMVI Strengths & weaknesses relative to competitors

COLUMVI Regulatory & Commercial Milestones

• COLUMVI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

COLUMVI Clinical Differentiation

• COLUMVI Efficacy & safety advantages over existing drugs
• COLUMVI Unique selling points

COLUMVI Market Report Highlights

• In the coming years, the COLUMVI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The COLUMVI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence COLUMVI’s dominance.
• Other emerging products for Diffuse large B cell lymphoma; as well as potential indication like Mantle-cell lymphoma, B-cell lymphoma, Chronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin’s lymphoma, Richter’s syndrome, and Haematological malignancies are expected to give tough market competition to COLUMVI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of COLUMVI in approved and potential indications.
• Analyse COLUMVI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted COLUMVI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of COLUMVI in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of COLUMVI? How strong is COLUMVI’s clinical and commercial performance?
• What is COLUMVI’s clinical trial status in each individual indications such as Diffuse large B cell lymphoma; as well as potential indication like Mantle-cell lymphoma, B-cell lymphoma, Chronic lymphocytic leukaemia, Follicular lymphoma, Non-Hodgkin’s lymphoma, Richter’s syndrome, and Haematological malignancies and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the COLUMVI Manufacturers?
• What are the key designations that have been granted to COLUMVI for approved and potential indications? How are they going to impact COLUMVI’s penetration in various geographies?
• What is the current and forecasted COLUMVI market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of COLUMVI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to COLUMVI for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is COLUMVI? What is the duration of therapy and what are the geographical variations in cost per patient?